nodes	percent_of_prediction	percent_of_DWPC	metapath
Cefazolin—ABCC4—Fluorouracil—urinary bladder cancer	0.19	0.303	CbGbCtD
Cefazolin—SLC22A11—Methotrexate—urinary bladder cancer	0.112	0.179	CbGbCtD
Cefazolin—ABCC4—Methotrexate—urinary bladder cancer	0.105	0.167	CbGbCtD
Cefazolin—ALB—Fluorouracil—urinary bladder cancer	0.0703	0.112	CbGbCtD
Cefazolin—SLC22A8—Methotrexate—urinary bladder cancer	0.0654	0.104	CbGbCtD
Cefazolin—SLC22A6—Methotrexate—urinary bladder cancer	0.0455	0.0727	CbGbCtD
Cefazolin—ALB—Methotrexate—urinary bladder cancer	0.0388	0.0619	CbGbCtD
Cefazolin—SLC22A8—urine—urinary bladder cancer	0.00688	0.171	CbGeAlD
Cefazolin—TPMT—prostate gland—urinary bladder cancer	0.00414	0.103	CbGeAlD
Cefazolin—TPMT—Phase II conjugation—GSTZ1—urinary bladder cancer	0.00365	0.0492	CbGpPWpGaD
Cefazolin—TPMT—seminal vesicle—urinary bladder cancer	0.0035	0.0872	CbGeAlD
Cefazolin—TPMT—Phase II conjugation—GSTO2—urinary bladder cancer	0.00346	0.0467	CbGpPWpGaD
Cefazolin—TPMT—Phase II conjugation—NAT1—urinary bladder cancer	0.00346	0.0467	CbGpPWpGaD
Cefazolin—TPMT—Phase II conjugation—UGT2B7—urinary bladder cancer	0.00317	0.0427	CbGpPWpGaD
Cefazolin—SLC22A11—renal system—urinary bladder cancer	0.00298	0.0743	CbGeAlD
Cefazolin—TPMT—renal system—urinary bladder cancer	0.00282	0.0703	CbGeAlD
Cefazolin—TPMT—urethra—urinary bladder cancer	0.00277	0.069	CbGeAlD
Cefazolin—ABCC4—prostate gland—urinary bladder cancer	0.00249	0.062	CbGeAlD
Cefazolin—SLC22A8—prostate gland—urinary bladder cancer	0.00247	0.0615	CbGeAlD
Cefazolin—SLC22A11—female reproductive system—urinary bladder cancer	0.00239	0.0595	CbGeAlD
Cefazolin—TPMT—Biological oxidations—GSTZ1—urinary bladder cancer	0.00214	0.0288	CbGpPWpGaD
Cefazolin—TPMT—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00211	0.0284	CbGpPWpGaD
Cefazolin—TPMT—vagina—urinary bladder cancer	0.00205	0.0509	CbGeAlD
Cefazolin—TPMT—Biological oxidations—GSTO2—urinary bladder cancer	0.00203	0.0273	CbGpPWpGaD
Cefazolin—TPMT—Biological oxidations—NAT1—urinary bladder cancer	0.00203	0.0273	CbGpPWpGaD
Cefazolin—TPMT—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.002	0.0269	CbGpPWpGaD
Cefazolin—TPMT—Phase II conjugation—NAT2—urinary bladder cancer	0.0019	0.0256	CbGpPWpGaD
Cefazolin—TPMT—Biological oxidations—UGT2B7—urinary bladder cancer	0.00185	0.025	CbGpPWpGaD
Cefazolin—ABCC4—Fluoropyrimidine Activity—TYMP—urinary bladder cancer	0.00185	0.025	CbGpPWpGaD
Cefazolin—TPMT—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00183	0.0246	CbGpPWpGaD
Cefazolin—SLC22A11—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC14A2—urinary bladder cancer	0.00176	0.0238	CbGpPWpGaD
Cefazolin—ABCC4—renal system—urinary bladder cancer	0.0017	0.0422	CbGeAlD
Cefazolin—SLC22A8—renal system—urinary bladder cancer	0.00168	0.0419	CbGeAlD
Cefazolin—TPMT—Biological oxidations—CYP4B1—urinary bladder cancer	0.00167	0.0225	CbGpPWpGaD
Cefazolin—TPMT—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00165	0.0222	CbGpPWpGaD
Cefazolin—TPMT—Phase II conjugation—HPGDS—urinary bladder cancer	0.00152	0.0204	CbGpPWpGaD
Cefazolin—TPMT—Phase II conjugation—GSTT1—urinary bladder cancer	0.00147	0.0198	CbGpPWpGaD
Cefazolin—ABCC4—Fluoropyrimidine Activity—RRM2—urinary bladder cancer	0.00145	0.0195	CbGpPWpGaD
Cefazolin—ABCC4—female reproductive system—urinary bladder cancer	0.00136	0.0338	CbGeAlD
Cefazolin—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC14A2—urinary bladder cancer	0.00135	0.0181	CbGpPWpGaD
Cefazolin—TPMT—lymph node—urinary bladder cancer	0.00132	0.0329	CbGeAlD
Cefazolin—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC14A2—urinary bladder cancer	0.00112	0.0151	CbGpPWpGaD
Cefazolin—TPMT—Biological oxidations—NAT2—urinary bladder cancer	0.00111	0.015	CbGpPWpGaD
Cefazolin—TPMT—Metapathway biotransformation—NAT2—urinary bladder cancer	0.00109	0.0148	CbGpPWpGaD
Cefazolin—TPMT—Phase II conjugation—GSTP1—urinary bladder cancer	0.00102	0.0137	CbGpPWpGaD
Cefazolin—TPMT—Phase II conjugation—GSTM1—urinary bladder cancer	0.000937	0.0126	CbGpPWpGaD
Cefazolin—TPMT—Biological oxidations—HPGDS—urinary bladder cancer	0.000887	0.012	CbGpPWpGaD
Cefazolin—TPMT—Biological oxidations—GSTT1—urinary bladder cancer	0.000861	0.0116	CbGpPWpGaD
Cefazolin—ABCC4—NRF2 pathway—UGT2B7—urinary bladder cancer	0.000851	0.0115	CbGpPWpGaD
Cefazolin—ABCC4—Fluoropyrimidine Activity—TYMS—urinary bladder cancer	0.000837	0.0113	CbGpPWpGaD
Cefazolin—ALB—lymph node—urinary bladder cancer	0.000821	0.0204	CbGeAlD
Cefazolin—SLC22A11—SLC-mediated transmembrane transport—SLC14A2—urinary bladder cancer	0.000802	0.0108	CbGpPWpGaD
Cefazolin—ABCC4—lymph node—urinary bladder cancer	0.000795	0.0198	CbGeAlD
Cefazolin—ABCC4—Fluoropyrimidine Activity—ERCC2—urinary bladder cancer	0.000778	0.0105	CbGpPWpGaD
Cefazolin—ABCC4—Fluoropyrimidine Activity—MTHFR—urinary bladder cancer	0.000731	0.00985	CbGpPWpGaD
Cefazolin—ALB—Folate Metabolism—SLC19A1—urinary bladder cancer	0.000618	0.00832	CbGpPWpGaD
Cefazolin—SLC22A8—SLC-mediated transmembrane transport—SLC14A2—urinary bladder cancer	0.000611	0.00824	CbGpPWpGaD
Cefazolin—TPMT—Biological oxidations—GSTP1—urinary bladder cancer	0.000597	0.00804	CbGpPWpGaD
Cefazolin—TPMT—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000588	0.00793	CbGpPWpGaD
Cefazolin—TPMT—Biological oxidations—GSTM1—urinary bladder cancer	0.000548	0.00739	CbGpPWpGaD
Cefazolin—TPMT—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000541	0.00729	CbGpPWpGaD
Cefazolin—Mouth ulceration—Doxorubicin—urinary bladder cancer	0.000521	0.00201	CcSEcCtD
Cefazolin—Hepatic function abnormal—Epirubicin—urinary bladder cancer	0.000517	0.002	CcSEcCtD
Cefazolin—Anaemia—Fluorouracil—urinary bladder cancer	0.000517	0.002	CcSEcCtD
Cefazolin—SLC22A6—SLC-mediated transmembrane transport—SLC14A2—urinary bladder cancer	0.00051	0.00688	CbGpPWpGaD
Cefazolin—Leukopenia—Gemcitabine—urinary bladder cancer	0.000509	0.00197	CcSEcCtD
Cefazolin—Hypertonia—Doxorubicin—urinary bladder cancer	0.000505	0.00195	CcSEcCtD
Cefazolin—Leukopenia—Fluorouracil—urinary bladder cancer	0.0005	0.00193	CcSEcCtD
Cefazolin—Somnolence—Thiotepa—urinary bladder cancer	0.00049	0.0019	CcSEcCtD
Cefazolin—Anaemia—Cisplatin—urinary bladder cancer	0.00049	0.00189	CcSEcCtD
Cefazolin—Dyspepsia—Thiotepa—urinary bladder cancer	0.000486	0.00188	CcSEcCtD
Cefazolin—Phlebitis—Doxorubicin—urinary bladder cancer	0.000485	0.00188	CcSEcCtD
Cefazolin—Convulsion—Fluorouracil—urinary bladder cancer	0.000484	0.00187	CcSEcCtD
Cefazolin—Decreased appetite—Thiotepa—urinary bladder cancer	0.000479	0.00185	CcSEcCtD
Cefazolin—Hepatic function abnormal—Doxorubicin—urinary bladder cancer	0.000478	0.00185	CcSEcCtD
Cefazolin—Fatigue—Thiotepa—urinary bladder cancer	0.000476	0.00184	CcSEcCtD
Cefazolin—Leukopenia—Cisplatin—urinary bladder cancer	0.000474	0.00183	CcSEcCtD
Cefazolin—Pain—Thiotepa—urinary bladder cancer	0.000472	0.00182	CcSEcCtD
Cefazolin—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.000464	0.00179	CcSEcCtD
Cefazolin—Confusional state—Fluorouracil—urinary bladder cancer	0.00046	0.00178	CcSEcCtD
Cefazolin—Convulsion—Cisplatin—urinary bladder cancer	0.000459	0.00178	CcSEcCtD
Cefazolin—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.000456	0.00176	CcSEcCtD
Cefazolin—Feeling abnormal—Thiotepa—urinary bladder cancer	0.000455	0.00176	CcSEcCtD
Cefazolin—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.000454	0.00176	CcSEcCtD
Cefazolin—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000451	0.00174	CcSEcCtD
Cefazolin—Anaemia—Etoposide—urinary bladder cancer	0.000449	0.00173	CcSEcCtD
Cefazolin—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.000447	0.00173	CcSEcCtD
Cefazolin—Anorexia—Gemcitabine—urinary bladder cancer	0.000442	0.00171	CcSEcCtD
Cefazolin—Urticaria—Thiotepa—urinary bladder cancer	0.000438	0.00169	CcSEcCtD
Cefazolin—ALB—FOXA2 and FOXA3 transcription factor networks—TFRC—urinary bladder cancer	0.000437	0.00589	CbGpPWpGaD
Cefazolin—Body temperature increased—Thiotepa—urinary bladder cancer	0.000436	0.00169	CcSEcCtD
Cefazolin—Abdominal pain—Thiotepa—urinary bladder cancer	0.000436	0.00169	CcSEcCtD
Cefazolin—Anorexia—Fluorouracil—urinary bladder cancer	0.000435	0.00168	CcSEcCtD
Cefazolin—Toxic epidermal necrolysis—Methotrexate—urinary bladder cancer	0.000435	0.00168	CcSEcCtD
Cefazolin—Leukopenia—Etoposide—urinary bladder cancer	0.000435	0.00168	CcSEcCtD
Cefazolin—Hypotension—Gemcitabine—urinary bladder cancer	0.000434	0.00168	CcSEcCtD
Cefazolin—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000432	0.00167	CcSEcCtD
Cefazolin—Loss of consciousness—Etoposide—urinary bladder cancer	0.000427	0.00165	CcSEcCtD
Cefazolin—Hypotension—Fluorouracil—urinary bladder cancer	0.000426	0.00165	CcSEcCtD
Cefazolin—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000423	0.00164	CcSEcCtD
Cefazolin—Blood creatinine increased—Epirubicin—urinary bladder cancer	0.000423	0.00164	CcSEcCtD
Cefazolin—ALB—Vitamin B12 Metabolism—MPO—urinary bladder cancer	0.000422	0.00569	CbGpPWpGaD
Cefazolin—Convulsion—Etoposide—urinary bladder cancer	0.000421	0.00163	CcSEcCtD
Cefazolin—Eosinophilia—Methotrexate—urinary bladder cancer	0.000413	0.0016	CcSEcCtD
Cefazolin—Abdominal pain upper—Epirubicin—urinary bladder cancer	0.000413	0.0016	CcSEcCtD
Cefazolin—Somnolence—Gemcitabine—urinary bladder cancer	0.000412	0.00159	CcSEcCtD
Cefazolin—Anorexia—Cisplatin—urinary bladder cancer	0.000412	0.00159	CcSEcCtD
Cefazolin—SLC22A11—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000407	0.00549	CbGpPWpGaD
Cefazolin—Aspartate aminotransferase increased—Epirubicin—urinary bladder cancer	0.000407	0.00157	CcSEcCtD
Cefazolin—Toxic epidermal necrolysis—Epirubicin—urinary bladder cancer	0.000407	0.00157	CcSEcCtD
Cefazolin—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000406	0.00157	CcSEcCtD
Cefazolin—Somnolence—Fluorouracil—urinary bladder cancer	0.000406	0.00157	CcSEcCtD
Cefazolin—Hypotension—Cisplatin—urinary bladder cancer	0.000404	0.00156	CcSEcCtD
Cefazolin—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000403	0.00156	CcSEcCtD
Cefazolin—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000402	0.00155	CcSEcCtD
Cefazolin—Fatigue—Gemcitabine—urinary bladder cancer	0.0004	0.00155	CcSEcCtD
Cefazolin—Confusional state—Etoposide—urinary bladder cancer	0.000399	0.00154	CcSEcCtD
Cefazolin—Pain—Gemcitabine—urinary bladder cancer	0.000397	0.00153	CcSEcCtD
Cefazolin—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000397	0.00153	CcSEcCtD
Cefazolin—Pancytopenia—Methotrexate—urinary bladder cancer	0.000396	0.00153	CcSEcCtD
Cefazolin—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000396	0.00153	CcSEcCtD
Cefazolin—Asthenia—Thiotepa—urinary bladder cancer	0.000396	0.00153	CcSEcCtD
Cefazolin—Blood creatinine increased—Doxorubicin—urinary bladder cancer	0.000392	0.00151	CcSEcCtD
Cefazolin—Neutropenia—Methotrexate—urinary bladder cancer	0.00039	0.00151	CcSEcCtD
Cefazolin—Pruritus—Thiotepa—urinary bladder cancer	0.00039	0.00151	CcSEcCtD
Cefazolin—Pain—Fluorouracil—urinary bladder cancer	0.00039	0.00151	CcSEcCtD
Cefazolin—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000388	0.0015	CcSEcCtD
Cefazolin—Eosinophilia—Epirubicin—urinary bladder cancer	0.000387	0.0015	CcSEcCtD
Cefazolin—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000382	0.00148	CcSEcCtD
Cefazolin—Abdominal pain upper—Doxorubicin—urinary bladder cancer	0.000382	0.00148	CcSEcCtD
Cefazolin—Anorexia—Etoposide—urinary bladder cancer	0.000378	0.00146	CcSEcCtD
Cefazolin—Diarrhoea—Thiotepa—urinary bladder cancer	0.000377	0.00146	CcSEcCtD
Cefazolin—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.000376	0.00146	CcSEcCtD
Cefazolin—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000376	0.00146	CcSEcCtD
Cefazolin—Decreased appetite—Cisplatin—urinary bladder cancer	0.000376	0.00145	CcSEcCtD
Cefazolin—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000376	0.00145	CcSEcCtD
Cefazolin—Pancytopenia—Epirubicin—urinary bladder cancer	0.000371	0.00143	CcSEcCtD
Cefazolin—Hypotension—Etoposide—urinary bladder cancer	0.00037	0.00143	CcSEcCtD
Cefazolin—Pain—Cisplatin—urinary bladder cancer	0.00037	0.00143	CcSEcCtD
Cefazolin—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000369	0.00143	CcSEcCtD
Cefazolin—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000367	0.00142	CcSEcCtD
Cefazolin—Renal failure—Methotrexate—urinary bladder cancer	0.000366	0.00141	CcSEcCtD
Cefazolin—TPMT—Metabolism—GSTZ1—urinary bladder cancer	0.000366	0.00493	CbGpPWpGaD
Cefazolin—Neutropenia—Epirubicin—urinary bladder cancer	0.000365	0.00141	CcSEcCtD
Cefazolin—Dizziness—Thiotepa—urinary bladder cancer	0.000365	0.00141	CcSEcCtD
Cefazolin—Stomatitis—Methotrexate—urinary bladder cancer	0.000363	0.0014	CcSEcCtD
Cefazolin—Urticaria—Fluorouracil—urinary bladder cancer	0.000362	0.0014	CcSEcCtD
Cefazolin—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000361	0.00139	CcSEcCtD
Cefazolin—Eosinophilia—Doxorubicin—urinary bladder cancer	0.000358	0.00138	CcSEcCtD
Cefazolin—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000356	0.00138	CcSEcCtD
Cefazolin—Somnolence—Etoposide—urinary bladder cancer	0.000352	0.00136	CcSEcCtD
Cefazolin—Vomiting—Thiotepa—urinary bladder cancer	0.000351	0.00136	CcSEcCtD
Cefazolin—Rash—Thiotepa—urinary bladder cancer	0.000348	0.00134	CcSEcCtD
Cefazolin—Dermatitis—Thiotepa—urinary bladder cancer	0.000347	0.00134	CcSEcCtD
Cefazolin—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000347	0.00134	CcSEcCtD
Cefazolin—TPMT—Metabolism—GSTO2—urinary bladder cancer	0.000346	0.00467	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—NAT1—urinary bladder cancer	0.000346	0.00467	CbGpPWpGaD
Cefazolin—Headache—Thiotepa—urinary bladder cancer	0.000346	0.00134	CcSEcCtD
Cefazolin—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000345	0.00133	CcSEcCtD
Cefazolin—Decreased appetite—Etoposide—urinary bladder cancer	0.000344	0.00133	CcSEcCtD
Cefazolin—ALB—Folate Metabolism—MPO—urinary bladder cancer	0.000344	0.00463	CbGpPWpGaD
Cefazolin—Pancytopenia—Doxorubicin—urinary bladder cancer	0.000343	0.00133	CcSEcCtD
Cefazolin—Renal failure—Epirubicin—urinary bladder cancer	0.000342	0.00132	CcSEcCtD
Cefazolin—Body temperature increased—Cisplatin—urinary bladder cancer	0.000342	0.00132	CcSEcCtD
Cefazolin—Fatigue—Etoposide—urinary bladder cancer	0.000342	0.00132	CcSEcCtD
Cefazolin—Stomatitis—Epirubicin—urinary bladder cancer	0.000339	0.00131	CcSEcCtD
Cefazolin—Pain—Etoposide—urinary bladder cancer	0.000339	0.00131	CcSEcCtD
Cefazolin—Neutropenia—Doxorubicin—urinary bladder cancer	0.000338	0.00131	CcSEcCtD
Cefazolin—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000336	0.0013	CcSEcCtD
Cefazolin—Haemoglobin—Methotrexate—urinary bladder cancer	0.000336	0.0013	CcSEcCtD
Cefazolin—Haemorrhage—Methotrexate—urinary bladder cancer	0.000334	0.00129	CcSEcCtD
Cefazolin—Hepatitis—Methotrexate—urinary bladder cancer	0.000334	0.00129	CcSEcCtD
Cefazolin—Asthenia—Gemcitabine—urinary bladder cancer	0.000333	0.00129	CcSEcCtD
Cefazolin—ABCC4—NRF2 pathway—NQO1—urinary bladder cancer	0.000328	0.00443	CbGpPWpGaD
Cefazolin—Pruritus—Gemcitabine—urinary bladder cancer	0.000328	0.00127	CcSEcCtD
Cefazolin—Nausea—Thiotepa—urinary bladder cancer	0.000328	0.00127	CcSEcCtD
Cefazolin—Feeling abnormal—Etoposide—urinary bladder cancer	0.000326	0.00126	CcSEcCtD
Cefazolin—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000325	0.00126	CcSEcCtD
Cefazolin—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000324	0.00125	CcSEcCtD
Cefazolin—Pruritus—Fluorouracil—urinary bladder cancer	0.000323	0.00125	CcSEcCtD
Cefazolin—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000319	0.00124	CcSEcCtD
Cefazolin—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000319	0.00123	CcSEcCtD
Cefazolin—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000317	0.00123	CcSEcCtD
Cefazolin—TPMT—Metabolism—UGT2B7—urinary bladder cancer	0.000317	0.00427	CbGpPWpGaD
Cefazolin—Renal failure—Doxorubicin—urinary bladder cancer	0.000317	0.00122	CcSEcCtD
Cefazolin—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000316	0.00122	CcSEcCtD
Cefazolin—Urticaria—Etoposide—urinary bladder cancer	0.000315	0.00122	CcSEcCtD
Cefazolin—Haemoglobin—Epirubicin—urinary bladder cancer	0.000314	0.00121	CcSEcCtD
Cefazolin—Stomatitis—Doxorubicin—urinary bladder cancer	0.000314	0.00121	CcSEcCtD
Cefazolin—Body temperature increased—Etoposide—urinary bladder cancer	0.000313	0.00121	CcSEcCtD
Cefazolin—Abdominal pain—Etoposide—urinary bladder cancer	0.000313	0.00121	CcSEcCtD
Cefazolin—Hepatitis—Epirubicin—urinary bladder cancer	0.000313	0.00121	CcSEcCtD
Cefazolin—Haemorrhage—Epirubicin—urinary bladder cancer	0.000313	0.00121	CcSEcCtD
Cefazolin—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000312	0.00121	CcSEcCtD
Cefazolin—SLC22A8—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000311	0.00419	CbGpPWpGaD
Cefazolin—Asthenia—Cisplatin—urinary bladder cancer	0.00031	0.0012	CcSEcCtD
Cefazolin—Dizziness—Fluorouracil—urinary bladder cancer	0.000302	0.00117	CcSEcCtD
Cefazolin—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000301	0.00116	CcSEcCtD
Cefazolin—ABCC4—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000298	0.00401	CbGpPWpGaD
Cefazolin—Diarrhoea—Cisplatin—urinary bladder cancer	0.000296	0.00114	CcSEcCtD
Cefazolin—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000296	0.00114	CcSEcCtD
Cefazolin—Vomiting—Gemcitabine—urinary bladder cancer	0.000295	0.00114	CcSEcCtD
Cefazolin—SLC22A11—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000295	0.00397	CbGpPWpGaD
Cefazolin—Rash—Gemcitabine—urinary bladder cancer	0.000293	0.00113	CcSEcCtD
Cefazolin—Dermatitis—Gemcitabine—urinary bladder cancer	0.000292	0.00113	CcSEcCtD
Cefazolin—Hypersensitivity—Etoposide—urinary bladder cancer	0.000292	0.00113	CcSEcCtD
Cefazolin—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000291	0.00112	CcSEcCtD
Cefazolin—Headache—Gemcitabine—urinary bladder cancer	0.000291	0.00112	CcSEcCtD
Cefazolin—Vomiting—Fluorouracil—urinary bladder cancer	0.00029	0.00112	CcSEcCtD
Cefazolin—Hepatitis—Doxorubicin—urinary bladder cancer	0.000289	0.00112	CcSEcCtD
Cefazolin—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000289	0.00112	CcSEcCtD
Cefazolin—Rash—Fluorouracil—urinary bladder cancer	0.000288	0.00111	CcSEcCtD
Cefazolin—Dermatitis—Fluorouracil—urinary bladder cancer	0.000287	0.00111	CcSEcCtD
Cefazolin—Headache—Fluorouracil—urinary bladder cancer	0.000286	0.00111	CcSEcCtD
Cefazolin—TPMT—Metabolism—CYP4B1—urinary bladder cancer	0.000285	0.00385	CbGpPWpGaD
Cefazolin—Asthenia—Etoposide—urinary bladder cancer	0.000284	0.0011	CcSEcCtD
Cefazolin—Pruritus—Etoposide—urinary bladder cancer	0.00028	0.00108	CcSEcCtD
Cefazolin—ABCC4—Fluoropyrimidine Activity—TP53—urinary bladder cancer	0.000278	0.00374	CbGpPWpGaD
Cefazolin—ABCC4—Platelet degranulation—IGF1—urinary bladder cancer	0.000277	0.00373	CbGpPWpGaD
Cefazolin—Nausea—Gemcitabine—urinary bladder cancer	0.000276	0.00107	CcSEcCtD
Cefazolin—Vomiting—Cisplatin—urinary bladder cancer	0.000275	0.00106	CcSEcCtD
Cefazolin—ABCC4—NRF2 pathway—GSTP1—urinary bladder cancer	0.000274	0.00369	CbGpPWpGaD
Cefazolin—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000273	0.00106	CcSEcCtD
Cefazolin—ALB—Selenium Micronutrient Network—MPO—urinary bladder cancer	0.000273	0.00368	CbGpPWpGaD
Cefazolin—Rash—Cisplatin—urinary bladder cancer	0.000273	0.00105	CcSEcCtD
Cefazolin—Dermatitis—Cisplatin—urinary bladder cancer	0.000272	0.00105	CcSEcCtD
Cefazolin—Diarrhoea—Etoposide—urinary bladder cancer	0.000271	0.00105	CcSEcCtD
Cefazolin—Nausea—Fluorouracil—urinary bladder cancer	0.000271	0.00105	CcSEcCtD
Cefazolin—TPMT—Metabolism—SLC19A1—urinary bladder cancer	0.000269	0.00363	CbGpPWpGaD
Cefazolin—Anaemia—Methotrexate—urinary bladder cancer	0.000269	0.00104	CcSEcCtD
Cefazolin—Flatulence—Epirubicin—urinary bladder cancer	0.000268	0.00104	CcSEcCtD
Cefazolin—ALB—SLC-mediated transmembrane transport—SLC14A2—urinary bladder cancer	0.000265	0.00357	CbGpPWpGaD
Cefazolin—ALB—Vitamin B12 Metabolism—SOD2—urinary bladder cancer	0.000265	0.00357	CbGpPWpGaD
Cefazolin—ABCC4—Response to elevated platelet cytosolic Ca2+—IGF1—urinary bladder cancer	0.000264	0.00355	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—PRSS3—urinary bladder cancer	0.000263	0.00354	CbGpPWpGaD
Cefazolin—Dizziness—Etoposide—urinary bladder cancer	0.000262	0.00101	CcSEcCtD
Cefazolin—Leukopenia—Methotrexate—urinary bladder cancer	0.00026	0.00101	CcSEcCtD
Cefazolin—SLC22A6—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000259	0.00349	CbGpPWpGaD
Cefazolin—Nausea—Cisplatin—urinary bladder cancer	0.000257	0.000993	CcSEcCtD
Cefazolin—Convulsion—Methotrexate—urinary bladder cancer	0.000252	0.000974	CcSEcCtD
Cefazolin—Vomiting—Etoposide—urinary bladder cancer	0.000252	0.000974	CcSEcCtD
Cefazolin—ABCC4—NRF2 pathway—GSTM1—urinary bladder cancer	0.000252	0.00339	CbGpPWpGaD
Cefazolin—Anaemia—Epirubicin—urinary bladder cancer	0.000252	0.000973	CcSEcCtD
Cefazolin—Agitation—Epirubicin—urinary bladder cancer	0.00025	0.000967	CcSEcCtD
Cefazolin—Rash—Etoposide—urinary bladder cancer	0.00025	0.000966	CcSEcCtD
Cefazolin—Dermatitis—Etoposide—urinary bladder cancer	0.00025	0.000965	CcSEcCtD
Cefazolin—Headache—Etoposide—urinary bladder cancer	0.000248	0.00096	CcSEcCtD
Cefazolin—Flatulence—Doxorubicin—urinary bladder cancer	0.000248	0.000959	CcSEcCtD
Cefazolin—Syncope—Epirubicin—urinary bladder cancer	0.000244	0.000944	CcSEcCtD
Cefazolin—Leukopenia—Epirubicin—urinary bladder cancer	0.000244	0.000942	CcSEcCtD
Cefazolin—SLC22A11—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.00024	0.00324	CbGpPWpGaD
Cefazolin—Confusional state—Methotrexate—urinary bladder cancer	0.000239	0.000925	CcSEcCtD
Cefazolin—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000239	0.000925	CcSEcCtD
Cefazolin—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000237	0.000918	CcSEcCtD
Cefazolin—Convulsion—Epirubicin—urinary bladder cancer	0.000236	0.000912	CcSEcCtD
Cefazolin—Nausea—Etoposide—urinary bladder cancer	0.000235	0.00091	CcSEcCtD
Cefazolin—ALB—Vitamin B12 Metabolism—MTHFR—urinary bladder cancer	0.000233	0.00315	CbGpPWpGaD
Cefazolin—Anaemia—Doxorubicin—urinary bladder cancer	0.000233	0.0009	CcSEcCtD
Cefazolin—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000232	0.000898	CcSEcCtD
Cefazolin—Agitation—Doxorubicin—urinary bladder cancer	0.000231	0.000895	CcSEcCtD
Cefazolin—Anorexia—Methotrexate—urinary bladder cancer	0.000226	0.000875	CcSEcCtD
Cefazolin—Syncope—Doxorubicin—urinary bladder cancer	0.000226	0.000873	CcSEcCtD
Cefazolin—Leukopenia—Doxorubicin—urinary bladder cancer	0.000225	0.000871	CcSEcCtD
Cefazolin—SLC22A8—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000225	0.00303	CbGpPWpGaD
Cefazolin—Confusional state—Epirubicin—urinary bladder cancer	0.000224	0.000866	CcSEcCtD
Cefazolin—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000222	0.000859	CcSEcCtD
Cefazolin—Hypotension—Methotrexate—urinary bladder cancer	0.000222	0.000857	CcSEcCtD
Cefazolin—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000221	0.000856	CcSEcCtD
Cefazolin—Shock—Epirubicin—urinary bladder cancer	0.000219	0.000845	CcSEcCtD
Cefazolin—Convulsion—Doxorubicin—urinary bladder cancer	0.000218	0.000844	CcSEcCtD
Cefazolin—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000217	0.000841	CcSEcCtD
Cefazolin—ALB—Folate Metabolism—SOD2—urinary bladder cancer	0.000216	0.00291	CbGpPWpGaD
Cefazolin—ABCC4—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000215	0.0029	CbGpPWpGaD
Cefazolin—Anorexia—Epirubicin—urinary bladder cancer	0.000212	0.000819	CcSEcCtD
Cefazolin—Somnolence—Methotrexate—urinary bladder cancer	0.000211	0.000816	CcSEcCtD
Cefazolin—TPMT—Metabolism—TYMP—urinary bladder cancer	0.00021	0.00283	CbGpPWpGaD
Cefazolin—Dyspepsia—Methotrexate—urinary bladder cancer	0.000209	0.000808	CcSEcCtD
Cefazolin—Hypotension—Epirubicin—urinary bladder cancer	0.000208	0.000802	CcSEcCtD
Cefazolin—Confusional state—Doxorubicin—urinary bladder cancer	0.000207	0.000801	CcSEcCtD
Cefazolin—Decreased appetite—Methotrexate—urinary bladder cancer	0.000206	0.000798	CcSEcCtD
Cefazolin—ALB—Folate Metabolism—GPX1—urinary bladder cancer	0.000206	0.00277	CbGpPWpGaD
Cefazolin—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000205	0.000795	CcSEcCtD
Cefazolin—Fatigue—Methotrexate—urinary bladder cancer	0.000205	0.000791	CcSEcCtD
Cefazolin—Pain—Methotrexate—urinary bladder cancer	0.000203	0.000785	CcSEcCtD
Cefazolin—Shock—Doxorubicin—urinary bladder cancer	0.000202	0.000782	CcSEcCtD
Cefazolin—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000201	0.000778	CcSEcCtD
Cefazolin—Somnolence—Epirubicin—urinary bladder cancer	0.000197	0.000763	CcSEcCtD
Cefazolin—Anorexia—Doxorubicin—urinary bladder cancer	0.000196	0.000757	CcSEcCtD
Cefazolin—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000196	0.000756	CcSEcCtD
Cefazolin—Dyspepsia—Epirubicin—urinary bladder cancer	0.000195	0.000756	CcSEcCtD
Cefazolin—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000194	0.00075	CcSEcCtD
Cefazolin—Decreased appetite—Epirubicin—urinary bladder cancer	0.000193	0.000747	CcSEcCtD
Cefazolin—Hypotension—Doxorubicin—urinary bladder cancer	0.000192	0.000742	CcSEcCtD
Cefazolin—Fatigue—Epirubicin—urinary bladder cancer	0.000191	0.00074	CcSEcCtD
Cefazolin—ALB—Folate Metabolism—MTHFR—urinary bladder cancer	0.00019	0.00256	CbGpPWpGaD
Cefazolin—Pain—Epirubicin—urinary bladder cancer	0.00019	0.000734	CcSEcCtD
Cefazolin—TPMT—Metabolism—NAT2—urinary bladder cancer	0.00019	0.00256	CbGpPWpGaD
Cefazolin—Urticaria—Methotrexate—urinary bladder cancer	0.000189	0.000729	CcSEcCtD
Cefazolin—Abdominal pain—Methotrexate—urinary bladder cancer	0.000188	0.000725	CcSEcCtD
Cefazolin—Body temperature increased—Methotrexate—urinary bladder cancer	0.000188	0.000725	CcSEcCtD
Cefazolin—SLC22A6—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000187	0.00253	CbGpPWpGaD
Cefazolin—SLC22A8—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000183	0.00247	CbGpPWpGaD
Cefazolin—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000183	0.000708	CcSEcCtD
Cefazolin—Somnolence—Doxorubicin—urinary bladder cancer	0.000183	0.000706	CcSEcCtD
Cefazolin—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000182	0.000702	CcSEcCtD
Cefazolin—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000181	0.000699	CcSEcCtD
Cefazolin—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000179	0.000691	CcSEcCtD
Cefazolin—Fatigue—Doxorubicin—urinary bladder cancer	0.000177	0.000685	CcSEcCtD
Cefazolin—Urticaria—Epirubicin—urinary bladder cancer	0.000176	0.000682	CcSEcCtD
Cefazolin—Pain—Doxorubicin—urinary bladder cancer	0.000176	0.000679	CcSEcCtD
Cefazolin—Body temperature increased—Epirubicin—urinary bladder cancer	0.000176	0.000679	CcSEcCtD
Cefazolin—Abdominal pain—Epirubicin—urinary bladder cancer	0.000176	0.000679	CcSEcCtD
Cefazolin—ABCC4—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000176	0.00237	CbGpPWpGaD
Cefazolin—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000175	0.000676	CcSEcCtD
Cefazolin—ALB—Selenium Micronutrient Network—SOD2—urinary bladder cancer	0.000171	0.00231	CbGpPWpGaD
Cefazolin—Asthenia—Methotrexate—urinary bladder cancer	0.00017	0.000658	CcSEcCtD
Cefazolin—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000169	0.000655	CcSEcCtD
Cefazolin—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000168	0.00065	CcSEcCtD
Cefazolin—Pruritus—Methotrexate—urinary bladder cancer	0.000168	0.000649	CcSEcCtD
Cefazolin—TPMT—Metabolism—RRM2—urinary bladder cancer	0.000164	0.00221	CbGpPWpGaD
Cefazolin—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000164	0.000633	CcSEcCtD
Cefazolin—ALB—Selenium Micronutrient Network—GPX1—urinary bladder cancer	0.000164	0.0022	CbGpPWpGaD
Cefazolin—Urticaria—Doxorubicin—urinary bladder cancer	0.000163	0.000631	CcSEcCtD
Cefazolin—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000162	0.000628	CcSEcCtD
Cefazolin—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000162	0.000628	CcSEcCtD
Cefazolin—Diarrhoea—Methotrexate—urinary bladder cancer	0.000162	0.000628	CcSEcCtD
Cefazolin—SLC22A11—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000162	0.00219	CbGpPWpGaD
Cefazolin—Asthenia—Epirubicin—urinary bladder cancer	0.000159	0.000616	CcSEcCtD
Cefazolin—Pruritus—Epirubicin—urinary bladder cancer	0.000157	0.000608	CcSEcCtD
Cefazolin—Dizziness—Methotrexate—urinary bladder cancer	0.000157	0.000607	CcSEcCtD
Cefazolin—SLC22A6—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000153	0.00206	CbGpPWpGaD
Cefazolin—Diarrhoea—Epirubicin—urinary bladder cancer	0.000152	0.000588	CcSEcCtD
Cefazolin—TPMT—Metabolism—ENO2—urinary bladder cancer	0.000152	0.00205	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—HPGDS—urinary bladder cancer	0.000152	0.00205	CbGpPWpGaD
Cefazolin—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000151	0.000585	CcSEcCtD
Cefazolin—ALB—Selenium Micronutrient Network—MTHFR—urinary bladder cancer	0.000151	0.00203	CbGpPWpGaD
Cefazolin—Vomiting—Methotrexate—urinary bladder cancer	0.000151	0.000583	CcSEcCtD
Cefazolin—Rash—Methotrexate—urinary bladder cancer	0.00015	0.000579	CcSEcCtD
Cefazolin—Dermatitis—Methotrexate—urinary bladder cancer	0.000149	0.000578	CcSEcCtD
Cefazolin—Headache—Methotrexate—urinary bladder cancer	0.000149	0.000575	CcSEcCtD
Cefazolin—Asthenia—Doxorubicin—urinary bladder cancer	0.000147	0.00057	CcSEcCtD
Cefazolin—TPMT—Metabolism—GSTT1—urinary bladder cancer	0.000147	0.00198	CbGpPWpGaD
Cefazolin—Dizziness—Epirubicin—urinary bladder cancer	0.000147	0.000568	CcSEcCtD
Cefazolin—Pruritus—Doxorubicin—urinary bladder cancer	0.000145	0.000562	CcSEcCtD
Cefazolin—Vomiting—Epirubicin—urinary bladder cancer	0.000141	0.000546	CcSEcCtD
Cefazolin—Nausea—Methotrexate—urinary bladder cancer	0.000141	0.000545	CcSEcCtD
Cefazolin—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000141	0.000544	CcSEcCtD
Cefazolin—Rash—Epirubicin—urinary bladder cancer	0.00014	0.000541	CcSEcCtD
Cefazolin—Dermatitis—Epirubicin—urinary bladder cancer	0.00014	0.000541	CcSEcCtD
Cefazolin—Headache—Epirubicin—urinary bladder cancer	0.000139	0.000538	CcSEcCtD
Cefazolin—Dizziness—Doxorubicin—urinary bladder cancer	0.000136	0.000525	CcSEcCtD
Cefazolin—ALB—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000135	0.00182	CbGpPWpGaD
Cefazolin—Nausea—Epirubicin—urinary bladder cancer	0.000132	0.00051	CcSEcCtD
Cefazolin—Vomiting—Doxorubicin—urinary bladder cancer	0.000131	0.000505	CcSEcCtD
Cefazolin—Rash—Doxorubicin—urinary bladder cancer	0.00013	0.000501	CcSEcCtD
Cefazolin—Dermatitis—Doxorubicin—urinary bladder cancer	0.000129	0.000501	CcSEcCtD
Cefazolin—Headache—Doxorubicin—urinary bladder cancer	0.000129	0.000498	CcSEcCtD
Cefazolin—ALB—Platelet degranulation—IGF1—urinary bladder cancer	0.000125	0.00169	CbGpPWpGaD
Cefazolin—SLC22A8—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000124	0.00167	CbGpPWpGaD
Cefazolin—ABCC4—Platelet activation, signaling and aggregation—IGF1—urinary bladder cancer	0.000123	0.00165	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—NQO1—urinary bladder cancer	0.000122	0.00165	CbGpPWpGaD
Cefazolin—Nausea—Doxorubicin—urinary bladder cancer	0.000122	0.000472	CcSEcCtD
Cefazolin—ALB—Response to elevated platelet cytosolic Ca2+—IGF1—urinary bladder cancer	0.000119	0.00161	CbGpPWpGaD
Cefazolin—ABCC4—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000119	0.0016	CbGpPWpGaD
Cefazolin—ALB—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000117	0.00157	CbGpPWpGaD
Cefazolin—ABCC4—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	0.000113	0.00152	CbGpPWpGaD
Cefazolin—ALB—Folate Metabolism—IL2—urinary bladder cancer	0.000112	0.00151	CbGpPWpGaD
Cefazolin—Cefdinir—MPO—urinary bladder cancer	0.000111	1	CrCbGaD
Cefazolin—ABCC4—Hemostasis—IFNA2—urinary bladder cancer	0.00011	0.00148	CbGpPWpGaD
Cefazolin—ABCC4—Ectoderm Differentiation—MYC—urinary bladder cancer	0.000108	0.00145	CbGpPWpGaD
Cefazolin—SLC22A6—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000103	0.00139	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—GSTP1—urinary bladder cancer	0.000102	0.00138	CbGpPWpGaD
Cefazolin—ALB—Vitamin B12 Metabolism—TNF—urinary bladder cancer	0.000101	0.00135	CbGpPWpGaD
Cefazolin—ALB—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	9.74e-05	0.00131	CbGpPWpGaD
Cefazolin—ALB—Selenium Micronutrient Network—PTGS2—urinary bladder cancer	9.63e-05	0.0013	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—TYMS—urinary bladder cancer	9.49e-05	0.00128	CbGpPWpGaD
Cefazolin—ABCC4—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	9.44e-05	0.00127	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—NCOR1—urinary bladder cancer	9.38e-05	0.00126	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—GSTM1—urinary bladder cancer	9.38e-05	0.00126	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—GPX1—urinary bladder cancer	8.98e-05	0.00121	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—ERCC2—urinary bladder cancer	8.82e-05	0.00119	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—MTHFR—urinary bladder cancer	8.29e-05	0.00112	CbGpPWpGaD
Cefazolin—ABCC4—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	8.24e-05	0.00111	CbGpPWpGaD
Cefazolin—ALB—Folate Metabolism—TNF—urinary bladder cancer	8.18e-05	0.0011	CbGpPWpGaD
Cefazolin—ALB—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	7.94e-05	0.00107	CbGpPWpGaD
Cefazolin—ABCC4—Hemostasis—PLAU—urinary bladder cancer	7.77e-05	0.00105	CbGpPWpGaD
Cefazolin—SLC22A11—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	7.59e-05	0.00102	CbGpPWpGaD
Cefazolin—ALB—Folate Metabolism—TP53—urinary bladder cancer	7.21e-05	0.000972	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—PPARG—urinary bladder cancer	6.72e-05	0.000906	CbGpPWpGaD
Cefazolin—ALB—Metabolism—GSTZ1—urinary bladder cancer	6.66e-05	0.000897	CbGpPWpGaD
Cefazolin—ALB—Selenium Micronutrient Network—TNF—urinary bladder cancer	6.5e-05	0.000876	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—CREBBP—urinary bladder cancer	6.46e-05	0.00087	CbGpPWpGaD
Cefazolin—ABCC4—Hemostasis—CREBBP—urinary bladder cancer	6.41e-05	0.000864	CbGpPWpGaD
Cefazolin—ABCC4—Hemostasis—IGF1—urinary bladder cancer	6.33e-05	0.000853	CbGpPWpGaD
Cefazolin—ALB—Metabolism—NAT1—urinary bladder cancer	6.31e-05	0.000851	CbGpPWpGaD
Cefazolin—ALB—Metabolism—GSTO2—urinary bladder cancer	6.31e-05	0.000851	CbGpPWpGaD
Cefazolin—ALB—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	6.21e-05	0.000837	CbGpPWpGaD
Cefazolin—ABCC4—Hemostasis—RHOA—urinary bladder cancer	5.8e-05	0.000781	CbGpPWpGaD
Cefazolin—SLC22A8—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	5.79e-05	0.00078	CbGpPWpGaD
Cefazolin—ALB—Metabolism—UGT2B7—urinary bladder cancer	5.77e-05	0.000778	CbGpPWpGaD
Cefazolin—ALB—Platelet activation, signaling and aggregation—IGF1—urinary bladder cancer	5.56e-05	0.000749	CbGpPWpGaD
Cefazolin—ABCC4—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	5.55e-05	0.000748	CbGpPWpGaD
Cefazolin—ALB—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	5.37e-05	0.000723	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—PTGS2—urinary bladder cancer	5.29e-05	0.000712	CbGpPWpGaD
Cefazolin—ALB—Metabolism—CYP4B1—urinary bladder cancer	5.2e-05	0.000701	CbGpPWpGaD
Cefazolin—ALB—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	5.09e-05	0.000686	CbGpPWpGaD
Cefazolin—ALB—Hemostasis—IFNA2—urinary bladder cancer	4.96e-05	0.000668	CbGpPWpGaD
Cefazolin—ALB—Metabolism—SLC19A1—urinary bladder cancer	4.91e-05	0.000662	CbGpPWpGaD
Cefazolin—ABCC4—Hemostasis—IL2—urinary bladder cancer	4.87e-05	0.000656	CbGpPWpGaD
Cefazolin—SLC22A6—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.83e-05	0.000651	CbGpPWpGaD
Cefazolin—ALB—Metabolism—PRSS3—urinary bladder cancer	4.78e-05	0.000645	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—PTEN—urinary bladder cancer	4.61e-05	0.000621	CbGpPWpGaD
Cefazolin—TPMT—Metabolism—EP300—urinary bladder cancer	4.4e-05	0.000592	CbGpPWpGaD
Cefazolin—ABCC4—Hemostasis—EP300—urinary bladder cancer	4.37e-05	0.000588	CbGpPWpGaD
Cefazolin—ALB—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	4.27e-05	0.000576	CbGpPWpGaD
Cefazolin—ABCC4—Hemostasis—SRC—urinary bladder cancer	4.25e-05	0.000572	CbGpPWpGaD
Cefazolin—ALB—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.84e-05	0.000517	CbGpPWpGaD
Cefazolin—ALB—Metabolism—TYMP—urinary bladder cancer	3.82e-05	0.000515	CbGpPWpGaD
Cefazolin—ALB—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	3.73e-05	0.000502	CbGpPWpGaD
Cefazolin—ALB—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.67e-05	0.000495	CbGpPWpGaD
Cefazolin—ALB—Hemostasis—PLAU—urinary bladder cancer	3.52e-05	0.000474	CbGpPWpGaD
Cefazolin—ABCC4—Hemostasis—KRAS—urinary bladder cancer	3.52e-05	0.000474	CbGpPWpGaD
Cefazolin—ALB—Metabolism—NAT2—urinary bladder cancer	3.46e-05	0.000466	CbGpPWpGaD
Cefazolin—ABCC4—Hemostasis—TP53—urinary bladder cancer	3.12e-05	0.000421	CbGpPWpGaD
Cefazolin—ABCC4—Hemostasis—HRAS—urinary bladder cancer	2.99e-05	0.000403	CbGpPWpGaD
Cefazolin—ALB—Metabolism—RRM2—urinary bladder cancer	2.99e-05	0.000402	CbGpPWpGaD
Cefazolin—ALB—Hemostasis—CREBBP—urinary bladder cancer	2.9e-05	0.000391	CbGpPWpGaD
Cefazolin—ALB—Hemostasis—IGF1—urinary bladder cancer	2.86e-05	0.000386	CbGpPWpGaD
Cefazolin—ALB—Metabolism—ENO2—urinary bladder cancer	2.77e-05	0.000373	CbGpPWpGaD
Cefazolin—ALB—Metabolism—HPGDS—urinary bladder cancer	2.77e-05	0.000373	CbGpPWpGaD
Cefazolin—ALB—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.75e-05	0.00037	CbGpPWpGaD
Cefazolin—ALB—Metabolism—GSTT1—urinary bladder cancer	2.68e-05	0.000361	CbGpPWpGaD
Cefazolin—ALB—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.64e-05	0.000356	CbGpPWpGaD
Cefazolin—ALB—Hemostasis—RHOA—urinary bladder cancer	2.62e-05	0.000354	CbGpPWpGaD
Cefazolin—ALB—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.51e-05	0.000338	CbGpPWpGaD
Cefazolin—ALB—Metabolism—NQO1—urinary bladder cancer	2.23e-05	0.0003	CbGpPWpGaD
Cefazolin—ALB—Hemostasis—IL2—urinary bladder cancer	2.2e-05	0.000297	CbGpPWpGaD
Cefazolin—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.16e-05	0.000291	CbGpPWpGaD
Cefazolin—ALB—Hemostasis—EP300—urinary bladder cancer	1.98e-05	0.000266	CbGpPWpGaD
Cefazolin—ALB—Hemostasis—SRC—urinary bladder cancer	1.92e-05	0.000259	CbGpPWpGaD
Cefazolin—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.89e-05	0.000254	CbGpPWpGaD
Cefazolin—ALB—Metabolism—GSTP1—urinary bladder cancer	1.86e-05	0.000251	CbGpPWpGaD
Cefazolin—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.8e-05	0.000242	CbGpPWpGaD
Cefazolin—ALB—Metabolism—TYMS—urinary bladder cancer	1.73e-05	0.000233	CbGpPWpGaD
Cefazolin—ALB—Metabolism—NCOR1—urinary bladder cancer	1.71e-05	0.00023	CbGpPWpGaD
Cefazolin—ALB—Metabolism—GSTM1—urinary bladder cancer	1.71e-05	0.00023	CbGpPWpGaD
Cefazolin—ALB—Metabolism—GPX1—urinary bladder cancer	1.64e-05	0.00022	CbGpPWpGaD
Cefazolin—ALB—Metabolism—ERCC2—urinary bladder cancer	1.61e-05	0.000216	CbGpPWpGaD
Cefazolin—ALB—Hemostasis—KRAS—urinary bladder cancer	1.59e-05	0.000214	CbGpPWpGaD
Cefazolin—ALB—Metabolism—MTHFR—urinary bladder cancer	1.51e-05	0.000203	CbGpPWpGaD
Cefazolin—ALB—Hemostasis—TP53—urinary bladder cancer	1.41e-05	0.000191	CbGpPWpGaD
Cefazolin—ALB—Hemostasis—HRAS—urinary bladder cancer	1.35e-05	0.000182	CbGpPWpGaD
Cefazolin—ALB—Metabolism—PPARG—urinary bladder cancer	1.22e-05	0.000165	CbGpPWpGaD
Cefazolin—ALB—Metabolism—CREBBP—urinary bladder cancer	1.18e-05	0.000158	CbGpPWpGaD
Cefazolin—ALB—Metabolism—PTGS2—urinary bladder cancer	9.63e-06	0.00013	CbGpPWpGaD
Cefazolin—ALB—Metabolism—PTEN—urinary bladder cancer	8.4e-06	0.000113	CbGpPWpGaD
Cefazolin—ALB—Metabolism—EP300—urinary bladder cancer	8.01e-06	0.000108	CbGpPWpGaD
